Takeda insider plans sale of 34,603 ADSs

Accepted by SEC EDGAR 08/06/2026 - 05:17 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Nicola Greenway, affiliated with Takeda Pharmaceutical Company Limited, has filed to sell up to 34,603 American Depositary Shares (ADSs) of Takeda through Interactive Brokers LLC on or after August 7, 2026, with an indicated aggregate market value of $578,562.16. The ADSs were acquired primarily via vested Restricted Stock Unit Awards and participation in an Employee Stock Purchase Plan. During the past three months, Greenway has already sold 7,348 ADSs for proceeds of $123,072.06.

Key Figures

Planned ADSs to be sold: 34,603 ADSs Aggregate market value of planned sale: $578,562.16 Recent ADSs sold: 7,348 ADSs +4 more

7 metrics

Planned ADSs to be sold 34,603 ADSs Maximum Takeda ADSs planned for sale via broker

Aggregate market value of planned sale $578,562.16 Value associated with 34,603 ADSs

Recent ADSs sold 7,348 ADSs Takeda ADSs sold on July 13, 2026

Proceeds from recent sale $123,072.06 Total for 7,348 ADSs sold during past 3 months

RSU vesting 2023 11,912 ADSs Restricted Stock Unit Awards vested on July 28, 2023

RSU vesting 2024 14,816 ADSs Restricted Stock Unit Awards vested on July 30, 2024

RSU vesting 2025 18,866 ADSs Restricted Stock Unit Awards vested on July 31, 2025

Key Terms

Form 144, American Depositary Shares (ADSs), Restricted Stock Unit Awards, Employee Stock Purchase Plan

4 terms

Form 144 regulatory

"144: Securities Information American Depositary Shares (ADSs)"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

American Depositary Shares (ADSs) financial

"144: Securities Information American Depositary Shares (ADSs)"

A U.S.-listed certificate that stands for a specific number of shares in a non‑U.S. company held by a U.S. bank, making the foreign stock tradable on American exchanges in dollars. Think of it like a local voucher that represents ownership of an overseas product — it lets U.S. investors buy and sell foreign companies without handling foreign currency or foreign brokerage accounts, but it can affect dividends, voting rights, fees, liquidity and exposure to currency and regulatory differences.

Restricted Stock Unit Awards financial

"ADSs | 07/28/2023 | Restricted Stock Unit Awards - Vested"

Restricted stock unit awards are company promises to deliver a specific number of shares to employees or service providers in the future once conditions—such as staying with the company for a set time or meeting performance targets—are met. They matter to investors because when the promises convert into actual shares they increase the total share count and can reduce earnings per share, while also aligning recipients’ interests with stock performance much like deferred pay that turns into ownership if goals are met.

Employee Stock Purchase Plan financial

"ADSs | 04/13/2023 | Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for Takeda (TAK) by Nicola Greenway disclose?

The filing shows Nicola Greenway plans to sell up to 34,603 Takeda ADSs through Interactive Brokers, with an indicated aggregate market value of $578,562.16, and details how these shares were acquired via RSU vesting and an employee stock purchase plan.

How many Takeda (TAK) ADSs is Nicola Greenway planning to sell under this Form 144?

Nicola Greenway plans to sell up to 34,603 ADSs. The filing lists these securities with an aggregate market value of $578,562.16 and an approximate sale date of August 7, 2026 on the NYSE through Interactive Brokers LLC.

When is the planned sale date for the Takeda (TAK) ADSs in Nicola Greenway’s Form 144?

The planned sale date is August 7, 2026. This date is disclosed as the approximate date of sale for up to 34,603 ADSs of Takeda Pharmaceutical Company Limited to be sold on the NYSE through Interactive Brokers LLC.

How were the Takeda (TAK) ADSs in Nicola Greenway’s Form 144 originally acquired?

The ADSs were acquired mainly through Restricted Stock Unit Awards that vested on several dates and through an Employee Stock Purchase Plan, with multiple purchase dates and relatively small cash-funded ADS acquisitions listed in the filing.

What recent Takeda (TAK) share sales has Nicola Greenway made before this Form 144?

In the past three months, Nicola Greenway sold 7,348 ADSs of Takeda on July 13, 2026 for total proceeds of $123,072.06. This prior sale is disclosed in the section covering securities sold during the past three months.

On which exchange and through which broker are the Takeda (TAK) ADSs expected to be sold?

The ADSs are expected to be sold on the NYSE through Interactive Brokers LLC. The Form 144 lists Interactive Brokers’ Greenwich, Connecticut office as the broker handling the planned sale of up to 34,603 Takeda ADSs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002123546
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Takeda Pharmaceutical Company Limited
SEC File Number	001-38757
Address of Issuer	1-1, Nihonbashi-Honcho 2-chome Chuo-ku, Tokyo JAPAN 103-8668
Phone	81-3-3278-2111
Name of Person for Whose Account the Securities are To Be Sold	Nicola Greenway
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Chief Human Resources Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares (ADSs)	Interactive Brokers LLC One Pickwick Plaza Greenwich, CT 06830	34603	578562.16	158131870	08/07/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADSs	07/28/2023	Restricted Stock Unit Awards - Vested	Takeda Pharmaceutical Company Limited			11912	07/28/2023	Compensation
ADSs	07/30/2024	Restricted Stock Unit Awards - Vested	Takeda Pharmaceutical Company Limited			14816	07/30/2024	Compensation
ADSs	07/31/2025	Restricted Stock Unit Awards - Vested	Takeda Pharmaceutical Company Limited			18866	07/31/2025	Compensation
ADSs	04/13/2023	Employee Stock Purchase Plan	Takeda Pharmaceutical Company Limited			132	04/13/2023	Cash
ADSs	10/11/2023	Employee Stock Purchase Plan	Takeda Pharmaceutical Company Limited			142	10/11/2023	Cash
ADSs	04/10/2024	Employee Stock Purchase Plan	Takeda Pharmaceutical Company Limited			159	04/10/2024	Cash
ADSs	04/10/2025	Employee Stock Purchase Plan	Takeda Pharmaceutical Company Limited			152	04/10/2025	Cash
ADSs	10/10/2024	Employee Stock Purchase Plan	Takeda Pharmaceutical Company Limited			165	10/10/2024	Cash
ADSs	04/13/2026	Employee Stock Purchase Plan	Takeda Pharmaceutical Company Limited			225	04/13/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Nicola Greenway 500 KENDALL STREET CAMBRIDGE, MA 02142	ADSs	07/13/2026	7348	123072.06

144: Remarks and Signature

Remarks	Sale during the past 3 months was conducted in order to satisfy tax obligations in connection with share vesting effective July 13, 2026. Date of such sale reflects the date on which the administrative agent initiated this process, and such sales may not have settled as of the date hereof.
Date of Notice	08/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Samuel Ntonme, by power of attorney for Nicola Greenway
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)